Dialysis industry news

Stories from the dialysis comunity across the globe.



FDA Says to Cut Cefepime Dose in Patients with Kidney Disease - Renal Business Today PDF Print

WASHINGTON—According to MedPage Today, the antibiotic cefepime (Maxipime) may cause a specific type of seizure in patients with kidney impairment when doses are not reduced appropriately, the U.S. Food and Drug Administration warned.

Nearly 60 cases of nonconvulsive status epilepticus have been reported to the FDA since cefepime was approved in 1996, the agency said in a drug safety communication.

In 58 of the 59 incidents, the patients had renal impairment, and, in 56, label recommendations for lowered doses were not followed. Most of the seizures occurred in patients older than 65.

Sixteen of the patients died, including two in whom the seizures might have contributed to the fatal outcome, according to the FDA. But the agency stopped short of concluding that failure to adjust cefepime dosages was a cause of any of the deaths.

The FDA has ordered that cefepime's label be revised to highlight the seizure risk in patients with renal impairment (those with creatinine clearance of ?60 mL/min) and reiterating the importance of dosage adjustments in such patients.

Clinicians with patients who have seizures while receiving cefepime should consider stopping the drug or reducing the dose in patients with renal impairment, the agency advised.

...

 
Supreme Court Upholds Healthcare Reform Law - Renal Business Today PDF Print
WASHINGTON—The U.S. Supreme Court ruled that the insurance provisions of the Patient Protection and Affordable Care Act are constitutional, handing President Barack Obama a major election-year victory and shunning 26 states that had sought to overturn the reform law, according to ModernHealthcare.com.

The court ruled that Congress has the power to compel individuals to purchase insurance as a tax on people who do not have health insurance.

"The individual mandate cannot be upheld as an exercise of Congress power under the Commerce Clause," Chief Justice John Roberts wrote in the majority opinion (PDF). "In this case however, it is reasonable to construe what Congress has done is increasing taxes on those who have a certain amount of income but choose to go without health insurance. Such legislation is within Congress' power to tax."

The landmark decisions end two years of legal uncertainty and clear the way for full implementation of the 906-page law. That includes establishing insurance exchanges in each state, prohibiting insurance companies from discriminating against the sick, and requiring nearly all Americans to prove on their income taxes that they carry health insurance starting in 2014.

The court struck down part of the Medicaid expansion.

...

 
Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress ... - Sacramento Bee PDF Print

UNION CITY, Calif., June 28, 2012 -- /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a company manufacturing point of care instrumentation and consumables for the medical, veterinary, and research markets, announced today that a leading international medical supplies sourcing and support company has entered into a definitive agreement with Abaxis to purchase up to 300 CLIA waived Piccolo Xpress Chemistry Analyzers. The Piccolo Xpress instruments will be deployed by a leading international biotechnology company in the course of conducting a four-year worldwide drug clinical trial. Initial orders for the Piccolo Xpress instruments have been received, and Abaxis expects to ship the full complement of the 300 instruments by the end of the year.

Clint Severson, chairman and CEO of Abaxis, commented, "We have been working closely with leading clinical research organizations (CROs) and pharmaceutical companies to incorporate real-time testing into clinical trials and we are pleased to have received our first orders. An important consideration in drug clinical trials is the impact on liver and renal function in trial participants. The Piccolo Xpress is the ideal point-of-care instrument to monitor real time liver and renal function to insure patient safety and accurate analysis of the efficacy of the drug compound being studied. We are pleased to have entered into this important new market."

Matt Rapp, Abaxis Sales Director, said, "We believe the 'real-time' diagnostic test information provided by the Piccolo Xpress may help reduce the cost of drug studies, as well as reduce the time to market for new pharmaceuticals. In particular, we believe that real-time liver and renal function information during the trial could improve patient safety, comfort and convenience, while reducing the time and cost associated with shipping patient samples to off-site reference laboratories."

Rick Betts, Director of US Medical Marketing, added, "Abaxis has actively been exploring a variety of approaches to broaden our markets for the Piccolo Xpress system. This pharmaceutical clinical trial project is consistent with our strategy of promoting to a wider audience the clinical, operational and cost-reducing benefits of lab-accurate real-time information for disease diagnosis, medication monitoring and disease management. We believe there are great opportunities ahead in this market segment."

About AbaxisAbaxis develops, manufactures, and sells clinical chemistry analyzers for use in any human patient-care or veterinary setting to provide rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use disposable plastic discs, called reagent discs, that contain all the chemicals required to perform a wide variety of panel tests of up to 14 individual analytes for human patients and up to 13 tests for veterinary patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The Company also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC) a specialty instrument to detect clotting disorders and to measure equine fibrinogen levels; a handheld instrument for the rapid assessment of certain critical care tests; and rapid point-of-care test for infectious diseases, such as Heartworm, Parvovirus, Lyme Disease and Giardia.  Also, the state-of-the-art commercial laboratory, Abaxis Veterinary Reference Laboratories (AVRL) provides routine laboratory testing as well as specialty testing for veterinarians nationwide. 

Private Securities Litigation Reform Act of 1995 This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

 

 

SOURCE Abaxis, Inc.

...

 
Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy ... - Sacramento Bee PDF Print

NEW YORK, June 28, 2012 -- /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis

http://www.reportlinker.com/p0832800/Renal-Dialysis-Equipment-Market-to-2017--Lower-Costs-and-Similar-Efficacy-Rates-as-Hemodialysis-to-Increase-Adoption-Rates-of-Peritoneal-Dialysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Devices

Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis

Summary

GBI Research's report, "Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis" shows rapid growth in the number of End Stage Renal Disease (ESRD) patients owing to the growing prevalence of diabetes, hypertension and an increasingly large elderly population are driving the market globally. Factors such as the improving standards of living in developing economies and longer life expectancies of dialysis patients, due to improved access to healthcare services are also expected to boost the market. The report provides key data, information and analysis on the global renal dialysis equipment market, covering the market landscape, competitive landscape and market trends relating to four renal dialysis equipment market categories: dialysis accessories, continuous renal replacement therapy machines, peritoneal dialysis solutions and hemodialysis machines. Providing comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics, the report also reviews the competitive landscape and gives a detailed analysis of the pipeline products in each category. Details of important merger and acquisition deals that have taken place in the renal dialysis equipment market are also reviewed. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

- Key geographies: the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Market size for four renal dialysis equipment market categories: dialysis accessories, continuous renal replacement therapy machines, peritoneal dialysis solutions and hemodialysis machines.

- Annualized market revenues data for 2003–2010, and forecasts for 2010–2017.

- Qualitative analysis of key market trends, market drivers, and restraints by each category within the renal dialysis equipment market.

- The report also covers information on the leading companies currently operating in the market, the competitive landscape, and the leading technologies.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the renal dialysis equipment market.

- Design and develop your product development, marketing and sales strategies.

- Capitalize on M&A opportunities by identifying key companies with the most innovative pipeline.

- Develop market entry and market expansion strategies.

- Identify the key companies that are best positioned to take advantage of emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying the products most likely to ensure a robust return.

- Identify, understand and capitalize on the next big thing in the renal dialysis equipment market landscape

- Make more informed business decisions from the insightful and in-depth analysis of the renal dialysis equipment market and the factors shaping it.

 

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Introduction 8

2.1 GBI Research Guidance 8

3 Renal Dialysis Equipment - Overview 9

3.1 Renal Dialysis Equipment 9

3.1.1 Continuous Renal Replacement Therapy Machines 9

3.1.2 Dialysis Accessories 9

3.1.3 Hemodialysis Machines 9

3.1.4 Peritoneal Dialysis Solutions 9

4 Renal Dialysis Equipment, Global - Market Characterization 10

4.1 Renal Dialysis Equipment, Global, Revenue ($m), 2003 - 2010 10

4.2 Renal Dialysis Equipment, Global, Revenue ($m), 2010–2017 11

4.3 Renal Dialysis Equipment, Global, Company Share (%), 2010 12

4.4 Renal Dialysis Equipment, Global, Market Trends 13

4.4.1 Peritoneal Dialysis to be Preferred over Hemodialysis in the Near Future 13

4.4.2 Rising Trend of Integrating Product Manufacturers and Service Providers 13

4.4.3 Wearable Artificial Kidney – an Upcoming Technology Trend 13

4.5 Renal Dialysis Equipment, Global, Market Dynamics 14

4.5.1 Market Drivers 14

4.5.2 Market Restraints 15

5 Renal Dialysis Equipment, Global - Category Analysis and Forecasts 16

5.1 Renal Dialysis Equipment, Continuous Renal Replacement Therapy, Global 17

5.2 Renal Dialysis Equipment, Dialysis Accessories, Global 19

5.2.1 Dialysis Accessories, Market Driver 21

5.2.2 Dialysis Accessories, Market Restraint 21

5.3 Renal Dialysis Equipment, Hemodialysis, Global 22

5.3.1 Hemodialysis Machines, Market Driver 24

5.3.2 Hemodialysis Machines, Market Restraint 24

5.4 Renal Dialysis Equipment, Peritoneal Dialysis Solutions, Global 25

5.4.1 Peritoneal Dialysis Solutions, Market Driver 27

5.4.2 Peritoneal Dialysis Solutions, Market Restraints 27

6 Renal Dialysis Equipment, Global - Country Analysis and Forecasts 28

6.1 Renal Dialysis Equipment, The US, Revenue ($m), 2003–2010 29

6.2 Renal Dialysis Equipment, The US, Revenue ($m), 2010–2017 30

6.3 Renal Dialysis Equipment, Canada, Revenue ($m), 2003–2010 31

6.4 Renal Dialysis Equipment, Canada, Revenue ($m), 2010–2017 32

6.5 Renal Dialysis Equipment, The UK, Revenue ($m), 2003–2010 33

6.6 Renal Dialysis Equipment, The UK, Revenue ($m), 2010–2017 34

6.7 Renal Dialysis Equipment, Germany, Revenue ($m), 2003–2010 35

6.8 Renal Dialysis Equipment, Germany, Revenue ($m), 2010–2017 36

6.9 Renal Dialysis Equipment, France, Revenue ($m), 2003–2010 37

6.10 Renal Dialysis Equipment, France, Revenue ($m), 2010–2017 38

6.11 Renal Dialysis Equipment, Italy, Revenue ($m), 2003–2010 39

6.12 Renal Dialysis Equipment, Italy, Revenue ($m), 2010–2017 40

6.13 Renal Dialysis Equipment, Spain, Revenue ($m), 2003–2010 41

6.14 Renal Dialysis Equipment, Spain, Revenue ($m), 2010–2017 42

6.15 Renal Dialysis Equipment, Brazil, Revenue ($m), 2003–2010 43

6.16 Renal Dialysis Equipment, Brazil, Revenue ($m), 2010–2017 44

6.17 Renal Dialysis Equipment, Australia, Revenue ($m), 2003–2010 45

6.18 Renal Dialysis Equipment, Australia, Revenue ($m), 2010–2017 46

6.19 Renal Dialysis Equipment, China, Revenue ($m), 2003–2010 47

6.20 Renal Dialysis Equipment, China, Revenue ($m), 2010–2017 48

6.21 Renal Dialysis Equipment, India, Revenue ($m), 2003–2010 49

6.22 Renal Dialysis Equipment, India, Revenue ($m), 2010–2017 50

6.23 Renal Dialysis Equipment, Japan, Revenue ($m), 2003–2010 51

6.24 Renal Dialysis Equipment, Japan, Revenue ($m), 2010–2017 52

7 Renal Dialysis Equipment, Global - Future Outlook 53

7.1 Epidemiology 53

7.2 Disease Burden 53

7.3 Costs 53

7.4 Peritoneal Dialysis versus Hemodialysis 54

8 Renal Dialysis Equipment, Global - Competitive Assessment 55

8.1 Renal Dialysis Equipment Market, Opportunities and Threats 55

8.2 Renal Dialysis Equipment Market, Key Market Participants 56

8.2.1 Fresenius Medical Care AG & Co. KGaA 56

8.2.2 Baxter International Inc. 59

8.2.3 Gambro AB 60

8.2.4 Nipro Corporation 62

8.2.5 B. Braun Melsungen AG 63

9 Renal Dialysis Equipment, Global - Product Pipeline Analysis 65

9.1 Profiles of Key Products Under Clinical Development 68

9.1.1 Theralite 68

9.1.2 Automated Peritoneal Dialysis Cycler – Next Generation 68

9.1.3 Home Hemodialysis System 69

9.1.4 AK 200 Ultra S 70

9.1.5 Artis System 70

9.1.6 OLpur MD 220 70

9.1.7 Wearable Artificial Kidney 71

10 Renal Dialysis Equipment, Global - Consolidation Landscape 74

10.1 Key Deals - Mergers and Acquisitions 75

10.1.1 Fresenius Medical Care Acquires Hema Metrics Crit-Line system business 75

10.1.2 Fresenius Medical Care Acquires Peritoneal Dialysis Business from Gambro 75

10.1.3 Fresenius Medical Acquires Renal Solutions 75

10.1.4 NxStage Medical Acquires Medisystems 75

10.1.5 Gambro Acquires Hemapure 76

10.2 Key Deals – Partnerships 76

10.2.1 Fresenius Medical Care Enters into an Agreement with Nikkiso 76

10.2.2 NxStage Signs Distribution Agreement with Spindial for System One 76

10.2.3 Interface Biologics Signs Exclusive License Option Agreement with Fresenius Medical Care 77

10.2.4 Gambro Enters into an Agreement with Debiotech 77

10.3 Key Deals – Private Equity/Venture Capital 77

10.3.1 EQT and Investor AB Acquires Gambro through Indap 77

11 Appendix 78

11.1 Definitions 78

11.1.1 Renal Dialysis Equipment 78

11.1.2 Hemodialysis Machines 78

11.1.3 Peritoneal Dialysis Solutions 78

11.1.4 Continuous Renal Replacement Therapy Machines 78

11.1.5 Dialysis Accessories 78

11.2 Acronyms 79

11.3 Sources 80

11.4 Research Methodology 81

11.4.1 Secondary Research 81

11.4.2 Primary Research 81

11.4.3 Models 82

11.4.4 Forecasts 82

11.4.5 Expert Panels 82

11.5 Contact Us 82

11.6 Disclaimer 83

 

1.1 List of Tables

Table 1: Renal Dialysis Equipment, Global, Revenue ($m), 2003-2010 10

Table 2: Renal Dialysis Equipment, Global, Revenue ($m), 2010-2017 11

Table 3: Renal Dialysis Equipment, Global, Company Revenue ($m), 2010 12

Table 4: Renal Dialysis Equipment, Continuous Renal Replacement Therapy, Global, Revenue ($m), 2003-2010 17

Table 5: Renal Dialysis Equipment, Continuous Renal Replacement Therapy, Global, Revenue ($m), 2010-2007 18

Table 6: Renal Dialysis Equipment, Dialysis Accessories, Global, Revenue ($m), 2003-2010 19

Table 7: Renal Dialysis Equipment, Dialysis Accessories, Global, Revenue ($m), 2010-2017 20

Table 8: Renal Dialysis Equipment, Hemodialysis, Global, Revenue ($m), 2003-2010 22

Table 9: Renal Dialysis Equipment, Hemodialysis, Global, Revenue ($m), 2010-2017 23

Table 10: Renal Dialysis Equipment, Peritoneal Dialysis Solutions, Global, Revenue ($m), 2003-2010 25

Table 11: Renal Dialysis Equipment, Peritoneal Dialysis Solutions, Global, Revenue ($m), 2010-2017 26

Table 12: Renal Dialysis Equipment, The US, Revenue ($m), 2003-2010 29

Table 13: Renal Dialysis Equipment, The US, Revenue ($m), 2010-2017 30

Table 14: Renal Dialysis Equipment, Canada, Revenue ($m), 2003-2010 31

Table 15: Renal Dialysis Equipment, Canada, Revenue ($m), 2010-2017 32

Table 16: Renal Dialysis Equipment, The UK, Revenue ($m), 2003-2010 33

Table 17: Renal Dialysis Equipment, The UK, Revenue ($m), 2010-2017 34

Table 18: Renal Dialysis Equipment, Germany, Revenue ($m), 2003-2010 35

Table 19: Renal Dialysis Equipment, Germany, Revenue ($m), 2010-2017 36

Table 20: Renal Dialysis Equipment, France, Revenue ($m), 2003-2010 37

Table 21: Renal Dialysis Equipment, France, Revenue ($m), 2010-2017 38

Table 22: Renal Dialysis Equipment, Italy, Revenue ($m), 2003-2010 39

Table 23: Renal Dialysis Equipment, Italy, Revenue ($m), 2010-2017 40

Table 24: Renal Dialysis Equipment, Spain, Revenue ($m), 2003-2010 41

Table 25: Renal Dialysis Equipment, Spain, Revenue ($m), 2010-2017 42

Table 26: Renal Dialysis Equipment, Brazil, Revenue ($m), 2003-2010 43

Table 27: Renal Dialysis Equipment, Brazil, Revenue ($m), 2010-2017 44

Table 28: Renal Dialysis Equipment, Australia, Revenue ($m), 2003-2010 45

Table 29: Renal Dialysis Equipment, Australia, Revenue ($m), 2010-2017 46

Table 30: Renal Dialysis Equipment, China, Revenue ($m), 2003-2010 47

Table 31: Renal Dialysis Equipment, China, Revenue ($m), 2010-2017 48

Table 32: Renal Dialysis Equipment, India, Revenue ($m), 2003-2010 49

Table 33: Renal Dialysis Equipment, India, Revenue ($m), 2010-2017 50

Table 34: Renal Dialysis Equipment, Japan, Revenue ($m), 2003-2010 51

Table 35: Renal Dialysis Equipment, Japan, Revenue ($m), 2010-2017 52

Table 36: Fresenius Medical Care AG & Co. KGaA, Key Marketed Products, 2011 57

Table 37: Baxter International Inc., Key Marketed Products, 2011 59

Table 38: Gambro AB, Key Marketed Products, 2011 61

Table 39: Nipro Corporation, Key Marketed Products, 2011 62

Table 40: B. Braun Melsungen AG, Key Marketed Products, 2011 63

Table 41: Renal Dialysis Equipment, Global, Product Pipeline Analysis 65

Table 42: Renal Dialysis Equipment, Global Pipeline Products, 2011- Table-1 66

Table 43: Renal Dialysis Equipment, Global Pipeline Products, 2011- Table-2 67

Table 44: Theralite, Product Status, 2011 68

Table 45: Automated Peritoneal Dialysis Cycler - Next Generation, Product Status, 2011 68

Table 46: Home Hemodialysis System, Product Status, 2011 69

Table 47: Home Hemodialysis System 69

Table 48: AK 200 Ultra S, Product Status, 2011 70

Table 49: Artis System, Product Status, 2011 70

Table 50: OLpur MD 220, Product Status, 2011 71

Table 51: OLpur MD 220, Clinical Trial, 2011 71

Table 52: Wearable Artificial Kidney, Product Status, 2011 72

Table 53: Wearable Artificial Kidney, Clinical Trial, 2011 73

Table 54: Renal Dialysis Equipment, Global: Consolidation Landscape 74

 

1.2 List of Figures

Figure 1: Renal Dialysis Equipment, Global, Revenue ($m), 2003–2010 10

Figure 2: Renal Dialysis Equipment, Global, Revenue ($m), 2010–2017 11

Figure 3: Renal Dialysis Equipment, Global, Company Share (%), 2010 12

Figure 4: Renal Dialysis Equipment, Global, Category Analysis and Forecasts 16

Figure 5: Renal Dialysis Equipment, Continuous Renal Replacement Therapy, Global, Revenue ($m), 2003–2010 17

Figure 6: Renal Dialysis Equipment, Continuous Renal Replacement Therapy, Global, Revenue ($m), 2010–2007 18

Figure 7: Renal Dialysis Equipment, Dialysis Accessories, Global, Revenue ($m), 2003–2010 19

Figure 8: Renal Dialysis Equipment, Dialysis Accessories, Global, Revenue ($m), 2010–2017 20

Figure 9: Renal Dialysis Equipment, Hemodialysis, Global, Revenue ($m), 2003–2010 22

Figure 10: Renal Dialysis Equipment, Hemodialysis, Global, Revenue ($m), 2010–2017 23

Figure 11: Renal Dialysis Equipment, Peritoneal Dialysis Solutions, Global, Revenue ($m), 2003–2010 25

Figure 12: Renal Dialysis Equipment, Peritoneal Dialysis Solutions, Global, Revenue ($m), 2010–2017 26

Figure 13: Renal Dialysis Equipment, Global, Country Analysis and Forecasts, 2003–2017 28

Figure 14: Renal Dialysis Equipment, The US, Revenue ($m), 2003–2010 29

Figure 15: Renal Dialysis Equipment, The US, Revenue ($m), 2010–2017 30

Figure 16: Renal Dialysis Equipment, Canada, Revenue ($m), 2003–2010 31

Figure 17: Renal Dialysis Equipment, Canada, Revenue ($m), 2010–2017 32

Figure 18: Renal Dialysis Equipment, The UK, Revenue ($m), 2003–2010 33

Figure 19: Renal Dialysis Equipment, The UK, Revenue ($m), 2010–2017 34

Figure 20: Renal Dialysis Equipment, Germany, Revenue ($m), 2003–2010 35

Figure 21: Renal Dialysis Equipment, Germany, Revenue ($m), 2010–2017 36

Figure 22: Renal Dialysis Equipment, France, Revenue ($m), 2003–2010 37

Figure 23: Renal Dialysis Equipment, France, Revenue ($m), 2010–2017 38

Figure 24: Renal Dialysis Equipment, Italy, Revenue ($m), 2003–2010 39

Figure 25: Renal Dialysis Equipment, Italy, Revenue ($m), 2010–2017 40

Figure 26: Renal Dialysis Equipment, Spain, Revenue ($m), 2003–2010 41

Figure 27: Renal Dialysis Equipment, Spain, Revenue ($m), 2010–2017 42

Figure 28: Renal Dialysis Equipment, Brazil, Revenue ($m), 2003–2010 43

Figure 29: Renal Dialysis Equipment, Brazil, Revenue ($m), 2010–2017 44

Figure 30: Renal Dialysis Equipment, Australia, Revenue ($m), 2003–2010 45

Figure 31: Renal Dialysis Equipment, Australia, Revenue ($m), 2010–2017 46

Figure 32: Renal Dialysis Equipment, China, Revenue ($m), 2003–2010 47

Figure 33: Renal Dialysis Equipment, China, Revenue ($m), 2010–2017 48

Figure 34: Renal Dialysis Equipment, India, Revenue ($m), 2003–2010 49

Figure 35: Renal Dialysis Equipment, India, Revenue ($m), 2010–2017 50

Figure 36: Renal Dialysis Equipment, Japan, Revenue ($m), 2003–2010 51

Figure 37: Renal Dialysis Equipment, Japan, Revenue ($m), 2010–2017 52

Figure 38: Renal Dialysis Equipment, Global, Company Share (%), 2010 55

Figure 39: Renal Dialysis Equipment, Global, Product Pipeline Analysis 65

Figure 40: Renal Dialysis Equipment, Global: Consolidation Landscape 2007–2011* 74

 

Companies mentioned

Fresenius Medical Care AG & Co. KGaA Baxter International Inc. Gambro AB Nipro Corporation B. Braun Melsungen AG

To order this report:Medical Devices Industry:Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg Reportlinker Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker

...

 
Withybush Hospital Renal Unit gets major upgrade - eGov monitor PDF Print
eGov monitor
The Minister for Health and Social Services, Lesley Griffiths has announced the grant, which will pay for a 21 station Renal Dialysis Unit within the hospital grounds. More patients will have the opportunity to undergo treatment locally, reducing the

...

 
<< Start < Prev 511 512 513 514 515 516 517 518 519 520 Next > End >>

Page 513 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.